First of all, the drug utilization prescribing data has been collected and used in many different ways for many years. The practice of collecting prescribing data from community pharmacies in Canada has probably gone on for 30 or 40 years. I think it's a very good example—and you've put your finger on the issue—to show that the critical issue is how that information gets used. The information is extremely useful to show us how drugs are actually being prescribed and used in the community.
People tend to forget that about 50% of prescriptions in Canada are paid for in the public sector; the others are in the private sector. The methods that are used give us one way of collecting information from both sectors so we can get a very complete picture of what is happening.
This has gone on, and there was relatively little concern about the issue until we saw the emergence of some of this data's being used to directly target marketing activities of the few individual physicians. I think when the data is used in aggregate, at a group level, there's less concern about it, but when it's used for commercial purposes to target individual physicians, that's an issue of concern.
The other important area is that I think the data that gets collected has to—